# US 6,294,661 B1 · Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,294,661 B1
- Document ID: US6294661B1
- Status: Granted
- Kind: B1
- Application number: 09/155,920
- Filed: 1999-03-05
- Granted: 2001-09-25
- Earliest claimed: 1996-05-14
- Assignees: SmithKline Beecham Corporation
- Inventors: Michael Terence Black; John Edward Hodgson; David Justin Charles Knowles; Richard O Nicholas; Robert King Stodola
- Web page: https://patentgrep.com/patent/US6294661B1

## CPC

- C07K 14/3156: {from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides RF-1 polypeptides and DNA (RNA) encoding RF-1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing RF-1 polypeptides to screen for antibacterial compounds.

## Claims

### Claim 1

An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence is at least 95% identical to SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 2 (depends on 1)

A vector comprising the isolated polynucleotide segment of claim 1.

### Claim 3 (depends on 2)

An isolated host cell comprising the vector of claim 2.

### Claim 4 (depends on 1)

The isolated polynucleotide segment of claim 1, wherein the polynucleotide sequence is at least 97% identical to SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 5 (depends on 1)

The isolated polynucleotide segment of claim 1, wherein the polynucleotide sequence is at least 99% identical to SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 6

An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence comprises SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 7 (depends on 6)

A vector comprising the isolated polynucleotide segment of claim 6.

### Claim 8 (depends on 7)

An isolated host cell comprising the vector of claim 7.

### Claim 9 (depends on 8)

A process for producing a polypeptide comprising culturing the host cell of claim 8 under conditions sufficient for the production of the polypeptide, wherein the polypeptide comprises SEQ ID NO:2.

### Claim 10 (depends on 6)

The isolated polynucleotide segment of claim 6 encoding a fusion polypeptide, wherein the fusion polypeptide comprises SEQ ID NO:2.

### Claim 11

An isolated polynucleotide segment comprising a polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NO:1, wherein the hybridization conditions include incubation at 42° C. in a solution comprising: 50% formamide, 5× SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1 × SSC at 65° C.; and, wherein the polynucleotide sequence is at least 95% identical to SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 12 (depends on 11)

The isolated polynucleotide segment of claim 11, wherein the first polynucleotide sequence is at least 97% identical to SEQ ID NO:1, wherein the polynucleotide sequence is not genomic DNA and wherein the polynucleotide sequence detects Streptococcus pneumoniae by hybridization.

### Claim 13

An isolated polynucleotide segment comprising a polynucleotide sequence, wherein the polynucleotide sequence encodes a polypeptide comprising SEQ ID NO:2, and wherein the polynucleotide sequence is not genomic DNA.

### Claim 14 (depends on 13)

A vector comprising the isolated polynucleotide segment of claim 13.

### Claim 15 (depends on 14)

An isolated host cell comprising the vector of claim 14.

### Claim 16 (depends on 15)

A process for producing a polypeptide comprising culturing the host cell of claim 15 under conditions sufficient for the production of the polypeptide, wherein the polypeptide comprises SEQ ID NO:2.

### Claim 17 (depends on 13)

The isolated polynucleotide segment of claim 13 encoding a fusion polypeptide, wherein the fusion polypeptide comprises SEQ ID NO:2.

### Claim 18

An isolated polynucleotide segment comprising a polynucleotide sequence, wherein the polynucleotide sequence encodes a polypeptide consisting of SEQ ID NO:2, and wherein the polynucleotide sequence is not genomic DNA.

### Claim 19 (depends on 18)

A vector comprising the isolated polynucleotide segment of claim 18.

### Claim 20 (depends on 19)

An isolated host cell comprising the vector of claim 19.

### Claim 21 (depends on 20)

A process for producing a polypeptide comprising culturing the host cell of claim 20 under conditions sufficient for the production of the polypeptide, wherein the polypeptide consists of SEQ ID NO:2.